Eli Lilly's most recent trend suggests a bearish bias. One trading opportunity on Eli Lilly is a Bear Call Spread using a strike $65.00 short call and a strike $70.00 long call offers a potential 18.2% return on risk over the next 38 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $65.00 by expiration. The full premium credit of $0.77 would be kept by the premium seller. The risk of $4.23 would be incurred if the stock rose above the $70.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Eli Lilly is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Eli Lilly is bearish.
The RSI indicator is at 30.33 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
Jay Leno new CNBC gig
Wed, 15 Oct 2014 12:45:00 GMT
Drug Analysts Mull End Of ‘Double Irish' Loophole
Tue, 14 Oct 2014 17:10:00 GMT
Insider Trading Alert – LLY, ROSE And SCCO Traded By Insiders
Wed, 08 Oct 2014 14:30:00 GMT
Novartis says 3 executives to leave after GSK, Lilly deals
Wed, 08 Oct 2014 07:41:10 GMT
Reuters – Swiss drugmaker Novartis AG said three members of its executive committee would leave the company following the completion of transactions with GlaxoSmithKline and Eli Lilly to divest three units. Novartis agreed on a series of deals worth over $25 billion in April, which include hiving off three smaller units – animal health, over-the-counter (OTC) drugs and vaccines. As part of the overhaul, Novartis is selling its animal health business to Eli Lilly for $5.4 billion and its vaccines excluding flu to GSK for $7.1 billion. Last week, EU antitrust regulators approved Lilly's purchase of the animal health division.
Eli Lilly Stops Developing Tabalumab Due to Efficacy Issues
Tue, 07 Oct 2014 20:30:04 GMT
Also on Market Tamer…
Follow Us on Facebook